Published in J Clin Oncol on April 15, 2002
Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer (2006) 2.33
Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg (2010) 1.94
Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res (2008) 1.52
Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer (2010) 1.36
Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. J Natl Cancer Inst (2013) 1.28
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol (2013) 1.18
Chemotherapy for gastric cancer. World J Gastroenterol (2006) 1.13
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer. Br J Cancer (2006) 1.11
Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer (2013) 1.08
First-line treatment with oxaliplatin and capecitabine in patients with advanced or metastatic oesophageal cancer: a phase II study. Br J Cancer (2007) 1.08
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release (2013) 1.06
Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol (2008) 1.05
Peritoneal carcinomatosis. World J Gastroenterol (2013) 1.04
Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surg Today (2013) 1.02
Treatment options in patients with metastatic gastric cancer: current status and future perspectives. World J Gastroenterol (2014) 1.02
Docetaxel: its role in current and future treatments for advanced gastric cancer. Gastric Cancer (2009) 1.00
A case of esophageal adenocarcinoma arising from the ectopic gastric mucosa in the thoracic esophagus. Rare Tumors (2010) 1.00
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer (2012) 0.99
Chemotherapy for advanced gastric cancer: slow but further progress. Cancer Res Treat (2005) 0.95
Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. Br J Cancer (2003) 0.94
Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. Br J Cancer (2004) 0.93
Current gene expression studies in esophageal carcinoma. Curr Genomics (2009) 0.93
Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer. Gastric Cancer (2011) 0.93
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts. Br J Cancer (2011) 0.92
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. Br J Cancer (2006) 0.92
Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. Gastrointest Cancer Res (2008) 0.90
Do delays between diagnosis and surgery in resectable oesophageal cancer affect survival? A study based on West Midlands cancer registration data. Br J Cancer (2006) 0.90
Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J Clin Oncol (2008) 0.90
Survival from cancer of the oesophagus in England and Wales up to 2001. Br J Cancer (2008) 0.89
Feasibility of quality of life assessment in patients with upper gastrointestinal tract cancer. Br J Cancer (2003) 0.89
Quality of life in the trastuzumab for gastric cancer trial. Oncologist (2014) 0.89
Phase II study of weekly paclitaxel by one-hour infusion for advanced gastric cancer. Surg Today (2008) 0.88
Systemic therapy for advanced gastric cancer: a clinical practice guideline. Curr Oncol (2011) 0.87
Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World J Gastroenterol (2013) 0.87
Eastern Canadian Colorectal Cancer Consensus Conference: setting the limits of resectable disease. Curr Oncol (2010) 0.87
Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer. Cancer Res Treat (2011) 0.86
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br J Cancer (2008) 0.86
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer (2009) 0.85
How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist (2014) 0.85
VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery. World J Surg (2011) 0.85
Four consecutive multicenter phase II trials of adjuvant chemoradiation in patients with completely resected high-risk gastric cancer: the experience of the German AIO/ARO/CAO group. J Cancer Res Clin Oncol (2008) 0.84
Chemoradiotherapy for esophageal cancer. Gastrointest Cancer Res (2009) 0.84
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. Br J Cancer (2003) 0.84
Progression-free survival and time to progression as surrogate markers of overall survival in patients with advanced gastric cancer: analysis of 36 randomized trials. Invest New Drugs (2011) 0.83
Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol (2013) 0.83
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. Br J Cancer (2004) 0.83
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. Br J Cancer (2004) 0.83
Longitudinal Quality-of-Life Analysis of RTOG 94-05 (Int 0123):A Phase III Trial of Definitive Chemoradiotherapy for Esophageal Cancer. Gastrointest Cancer Res (2011) 0.82
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trial. Br J Cancer (2004) 0.82
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. Gastric Cancer (2013) 0.82
Advanced gastric cancer: an update and future directions. Gastrointest Cancer Res (2008) 0.81
Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin. J Cancer Res Clin Oncol (2008) 0.80
A pilot study of irinotecan (CPT-11) as single-agent therapy in patients with locally advanced or metastatic esophageal carcinoma. Int J Colorectal Dis (2003) 0.80
Epirubicin, cisplatin, and fluorouracil in gastric and esophageal cancer: a step ahead? J Clin Oncol (2002) 0.80
Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C. Br J Cancer (2003) 0.80
Neoadjuvant chemotherapy with FOLFOX4 regimen to treat advanced gastric cancer improves survival without increasing adverse events: a retrospective cohort study from a Chinese center. ScientificWorldJournal (2014) 0.79
Critical appraisal of trastuzumab in treatment of advanced stomach cancer. Cancer Manag Res (2011) 0.79
Treatment outcome of nimotuzumab plus chemotherapy in advanced cancer patients: a single institute experience. Oncotarget (2016) 0.79
Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer. J Cancer Res Clin Oncol (2010) 0.79
Surgical treatment of peritoneal carcinomatosis from gastric cancer. Int J Surg Oncol (2012) 0.79
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. J Clin Oncol (2016) 0.78
Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastric Cancer (2012) 0.78
Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors. J Cancer Res Clin Oncol (2014) 0.78
Chemotherapy in metastatic gastric cancer: population-based perceptions and practice patterns of medical oncologists. Br J Cancer (2004) 0.78
Recent advances in chemotherapy for advanced gastric cancer. World J Gastrointest Oncol (2010) 0.78
Capecitabine or infusional 5-fluorouracil for gastroesophageal cancer: a cost-consequence analysis. Curr Oncol (2011) 0.78
Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis. Springerplus (2015) 0.77
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol (2016) 0.77
Palliative Radiotherapy in the Presence of Well-Controlled Metastatic Disease after Initial Chemotherapy May Prolong Survival in Patients with Metastatic Esophageal and Gastric Cancer. Cancer Res Treat (2015) 0.77
Review of docetaxel in the treatment of gastric cancer. Ther Clin Risk Manag (2008) 0.76
Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer. Br J Cancer (2008) 0.76
A critical analysis of the cytoreductive surgery with hyperthermic intraperitoneal chemotherapy combo in the clinical management of advanced gastric cancer: an effective multimodality approach with scope for improvement. Transl Gastroenterol Hepatol (2016) 0.75
Phase I trial of weekly cisplatin, irinotecan and paclitaxel in patients with advanced gastrointestinal cancer. Invest New Drugs (2008) 0.75
LRP5 polymorphism-A potential predictor of the clinical outcome in advanced gastric cancer patients treated with EOF regimen. Chin J Cancer Res (2014) 0.75
The BC Cancer Agency Compassionate Access Program: outcome analysis of patients with esophagogastric cancer. Curr Oncol (2009) 0.75
'Trial Exegesis': Methods for Synthesizing Clinical and Patient Reported Outcome (PRO) Data in Trials to Inform Clinical Practice. A Systematic Review. PLoS One (2016) 0.75
Survival from cancer of the stomach in England and Wales up to 2001. Br J Cancer (2008) 0.75
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma. Cancer Med (2016) 0.75
Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer. Med Sci Monit (2017) 0.75
Comparison of neoadjuvant oral chemotherapy with UFT plus Folinic acid or Capecitabine concomitant with radiotherapy on locally advanced rectal cancer. Rep Pract Oncol Radiother (2012) 0.75
A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma. Oncotarget (2016) 0.75
Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma. Onco Targets Ther (2016) 0.75
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. Br J Cancer (2006) 0.75
A population-based observational study on the factors associated with the completion of palliative chemotherapy among patients with oesophagogastric cancer. BMJ Open (2015) 0.75
Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer. J Clin Oncol (2002) 0.75
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemother Pharmacol (2008) 0.75
Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer Res Clin Oncol (2016) 0.75
Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma. Gastric Cancer (2012) 0.75
Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer. Gastric Cancer (2010) 0.75
Neoadjuvant Therapy for Esophageal Adenocarcinoma in the Community Setting-Practice and Outcomes. Front Oncol (2017) 0.75
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol (2000) 16.83
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet (2000) 12.56
On the Interpretation of Multi-Hit Survival Curves. Proc Natl Acad Sci U S A (1949) 5.96
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol (1997) 5.89
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer (2001) 5.36
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol (2001) 5.25
Insulin biosynthesis: evidence for a precursor. Science (1967) 5.05
The epic project: developing national evidence-based guidelines for preventing healthcare associated infections. Phase I: Guidelines for preventing hospital-acquired infections. Department of Health (England). J Hosp Infect (2001) 4.95
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst (1998) 4.65
HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet (2004) 4.40
Bap, a Staphylococcus aureus surface protein involved in biofilm formation. J Bacteriol (2001) 4.18
Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol (2002) 3.91
Biotechnology awareness study, Part 1: Where scientists get their information. Bull Med Libr Assoc (1991) 3.85
The enterococcal surface protein, Esp, is involved in Enterococcus faecalis biofilm formation. Appl Environ Microbiol (2001) 3.48
Patient satisfaction after anaesthesia and surgery: results of a prospective survey of 10,811 patients. Br J Anaesth (2000) 3.46
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer (1998) 3.36
Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol (2009) 3.33
Effect of reactive pharmacy intervention on quality of hospital prescribing. BMJ (1990) 3.25
Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol (2003) 3.10
Single breath diffusing capacity in a representative sample of the population of Michigan, a large industrial state. Predicted values, lower limits of normal, and frequencies of abnormality by smoking history. Am Rev Respir Dis (1983) 2.83
C-type virus released from cultured human rhabdomyosarcoma cells. Nat New Biol (1972) 2.78
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol (1996) 2.76
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol (1997) 2.71
Silent MRI infarcts and the risk of future stroke: the cardiovascular health study. Neurology (2001) 2.55
Identification of the class I genes of the mouse major histocompatibility complex by DNA-mediated gene transfer. Nature (1982) 2.48
Radiographic interpretation by nurse practitioners in a minor injuries unit. J Accid Emerg Med (1996) 2.44
Is a low leptin concentration, a low resting metabolic rate, or both the expression of the "thrifty genotype"? Results from Mexican Pima Indians. Am J Clin Nutr (1998) 2.42
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol (2005) 2.41
Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab (1996) 2.40
Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer (2000) 2.34
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol (2005) 2.33
Bile acid transformations by microbial strains belonging to genera found in intestinal contents. Acta Pathol Microbiol Scand (1967) 2.33
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 2.31
Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol (2000) 2.29
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet (1991) 2.26
Honesty, perception and population divergence in sexually selected traits. Proc Biol Sci (1993) 2.26
From quantity to quality: the central cardiac audit database project. Heart (1999) 2.23
13C/31P NMR studies on the mechanism of insulin resistance in obesity. Diabetes (1998) 2.21
A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol (1998) 2.18
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.17
Evolution of ecological differences in the Old World leaf warblers. Nature (1992) 2.16
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut (2011) 2.14
Why do women attend familial breast cancer clinics? J Med Genet (2000) 2.13
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. Br J Cancer (2009) 2.13
Global impact of influenza virus on cellular pathways is mediated by both replication-dependent and -independent events. J Virol (2001) 2.13
Management of carcinomas of the upper gastrointestinal tract. BMJ (1994) 2.12
Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 2.12
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens. Eur J Cancer (1996) 2.11
Histone H3 phosphorylation and expression of cyclins A and B1 measured in individual cells during their progression through G2 and mitosis. Cytometry (1998) 2.11
A report on genetic registers. Based on the report of the Clinical Genetics Society Working Party. J Med Genet (1978) 2.09
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist. Lancet (1987) 2.09
Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial. Eur J Cancer (2006) 2.09
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil. J Clin Oncol (1996) 2.08
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol (1995) 2.08
Prevalence of disease among vinyl chloride and polyvinyl chloride workers. Ann N Y Acad Sci (1975) 2.04
Stimulus selection in animal discrimination learning. J Exp Psychol (1968) 2.03
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol (1994) 2.02
Detection of ambulatory ischaemia is not of practical clinical value in the routine management of patients with stable angina. A long-term follow-up study. Eur Heart J (1995) 1.97
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer (2004) 1.94
Traditional risk factors and ischemic stroke in young adults: the Baltimore-Washington Cooperative Young Stroke Study. Arch Neurol (1996) 1.94
Replication-defective chimeric helper proviruses and factors affecting generation of competent virus: expression of Moloney murine leukemia virus structural genes via the metallothionein promoter. Mol Cell Biol (1987) 1.94
Randomized trial of a specialist genetic assessment service for familial breast cancer. J Natl Cancer Inst (2000) 1.92
Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis. Medicine (Baltimore) (1991) 1.89
Risk of cancer among offspring of childhood-cancer survivors. Association of the Nordic Cancer Registries and the Nordic Society of Paediatric Haematology and Oncology. N Engl J Med (1998) 1.87
Blue babies and nitrate-contaminated well water. Environ Health Perspect (2000) 1.82
Nationwide cerebrovascular disease morbidity study. Stroke (1972) 1.82
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer (2005) 1.81
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer (1999) 1.80
Proliferation of human lymphocytes in culture. Nature (1966) 1.76
Helicobacter pylori infection and chronic gastritis in gastric cancer. J Clin Pathol (1992) 1.76
A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol) (2007) 1.75